The ␣3 subunit gene was one of the first neuronal nicotinic acetylcholine receptor (nAChR) subunits to be cloned (Boulter et al., 1986) , but direct evidence of ␣3 subunit contributions to mammalian central nAChR populations has not been presented. The studies reported here used mice engineered to contain a null mutation in the ␣3 nAChR subunit gene (Xu et al., 1999) to examine the involvement of the ␣3 subunit in central nAChR populations. Heterologously expressed ␣3␤2 and ␣3␤4 nAChRs are pharmacologically similar to native [ 
I]␣-conotoxin MII (␣-CtxMII)-binding and 3-(2(S)-azetidinylmethoxy)pyridine dihydrochloride (A85380)-resistant [
125 I]epibatidine-binding nAChR subtypes, respectively. The hypothesis that both native sites are ␣3-subtype nAChRs was tested using quantitative autoradiography in ␣3-null mutant mice. Somewhat surprisingly, deletion of the ␣3 nAChR subunit gene did not affect expression of the great majority of [ ]epibatidine-binding nAChRs were dependent on ␣3 gene expression, suggesting that they do indeed correspond to an ␣3 nAChR subtype. However, widespread but lower levels of ␣3-independent A85380-resistant [ 125 I]epibatidine binding were also seen. Again, this may indicate the existence of an additional, minor population of non-␣3 A85380-resistant sites.
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Nicotinic acetylcholine receptors (nAChRs) are involved in normal CNS functions, including analgesia, cognition, reward, and motor control (Decker et al., 1995) , and have been implicated in many of the diverse behavioral effects of nicotine in mammals (Stolerman, 1990) . It is generally accepted that nAChRs are homopentameric or heteropentameric assemblies of homologous subunits and that different combinations of subunits produce distinct nAChR subtypes with diverse biophysical and pharmacological properties (Lindstrom et al., 1996) . The potential to form functionally distinct pentamers, combined with differential expression of nAChR subtypes across the brain (Wada et al., 1989; Marks et al., 1992; Whiteaker et al., 2000a) , underlies the rich variety of effects and roles attributed to nAChRs.
Epibatidine is a nicotinic agonist with high (picomolar) affinity at many mammalian nAChR subtypes (Badio and Daly, 1994; Houghtling et al., 1995; Perry and Kellar, 1995; Flores et al., 1996; Davila-Garcia et al., 1997; Marks et al., 1998; Whiteaker et al., 2000a,b) . The majority of high-affinity epibatidine-binding sites are potently inhibited by the nicotinic agonist cytisine (cytisinesensitive sites; K i ϭ 0.29 nM) (Marks et al., 1998 (Whiting and Lindstrom, 1987; Flores et al., 1992; Picciotto et al., 1995; Marubio et al., 1999) . The remaining high-affinity epibatidine-binding sites exhibit much lower cytisine affinity (cytisine-resistant sites; K i Ͼ 10 nM) (Marks et al., 1998; Whiteaker et al., 2000a,b) . Some cytisineresistant sites are highly sensitive to the nicotinic antagonist ␣-conotoxin MII (␣-CtxMII) and may be directly identified using [
125 I]␣-CtxMII (Whiteaker et al., 2000b) . A second population of cytisine-resistant sites that is unaffected by high (3 M) concentrations of ␣-CtxMII and is unusually resistant to inhibition by the nicotinic agonist 3-(2( S)-azetidinylmethoxy)pyridine dihydrochloride (A85380) (Abreo et al., 1996) has also been identified (Whiteaker et al., 2000a) . Their low A85380 affinity may be used to isolate them pharmacologically from other cytisine-sensitive and -resistant epibatidine-binding sites (A85380-resistant sites). The distribution and pharmacology of both cytisine-resistant populations are suggestive of ␣3* nAChRs (Whiteaker, 2000a,b) , but concrete evidence of ␣3 involvement has not been provided in either case.
The purpose of this study was to investigate the involvement of the ␣3 nAChR subunit in the expression of the two cytisineresistant populations described above using mice engineered to lack the ␣3 nAChR subunit gene (Xu et al., 1999) .
MATERIALS AND METHODS

Animals.
Mice engineered to contain a null mutation in the ␣3 nAChR subunit gene (Xu et al., 1999) were bred at the Division of Neuroscience, Baylor College of Medicine, in accordance with procedures approved by the local Animal C are and Utilization committee.
Materials. [ 125 I]Epibatidine (specific activity, 2200 C i /mmol) was ob-tained from DuPont N EN (Boston, M A). (Ϫ)-Nicotine bitartrate was bought from BDH Chemicals (Poole, UK). A85380 was supplied by Research Biochemicals (Natick, M A). ␣-C txM II was synthesized as described previously (C artier et al., 1996) (Pauly et al., 1989; Whiteaker et al., 2000a) . Mice (8 d of age) of each ␣3 genotype (␣3 ϩ/ϩ , ␣3 ϩ/Ϫ , and ␣3 Ϫ/Ϫ ) were decapitated, and each brain was removed from the skull and rapidly frozen by immersion in isopentane (Ϫ35°C, 10 sec). Tissue was collected from mice from a single litter (2ϫ ␣3 ϩ/ϩ , 6ϫ ␣3 ϩ/Ϫ , and 2ϫ ␣3 Ϫ/Ϫ ). Tissue sections (10 m thick) were prepared from frozen, unfixed tissue using a Leica (Nussloch, Germany) C M1850 cryostat /microtome and were thawmounted onto gelatin /poly-L-lysine-subbed glass microscope slides (Richard Allen, Richland, M I).
Before exposure to [ 125 I]␣-C txM II (0.5 nM), sections were incubated in binding buffer (144 mM NaC l, 1.5 mM KC l; 2 mM CaCl 2 , 1 mM MgSO 4 , 20 mM H EPES, 0.1% w/ v BSA, pH 7.5) plus 1 mM PMSF (to inactivate endogenous serine proteases) at 22°C for 15 min. For all [ 125 I]␣-C txM IIbinding reactions, the standard binding buffer was supplemented with 5 mM EDTA, 5 mM EGTA, and 10 g /ml each of aprotinin, leupeptin trifluoroacetate, and pepstatin A to protect the ligand from endogenous proteases. A separate series of sections from each mouse was used to determine nonspecific [ Sections were initially dried with a stream of air and subsequently by overnight storage (22°C) under vacuum. Mounted, desiccated sections were apposed to Amersham Hyperfilm ␤-Max. Because large variations in ligand binding, and thus signal intensity, were observed, several film exposures were made for each binding condition to ensure that all measurements could be made within the accurate recording range of the film (3-7 d for [
125 I]␣-C txM II-labeled sections; 5-96 hr for [
125 I]epibatidine-labeled sections). To allow quantification, each film was also exposed to 125 I autoradiography microscale standards of defined specific activity.
After the films had been exposed to the sections for an appropriate length of time, they were developed and signal intensity in selected brain regions was measured by digital image analysis. Films were illuminated using a Northern Light (Ontario, C anada) light box, and autoradiographic images of the sections and standards were captured using a CCD imager camera. Signal intensity was determined using N IH Image 1.61 software. Where possible, six independent measurements from different tissue sections were made for each brain region, under each incubation condition, for each mouse. For each subject, the absorbance measurements from each brain area were used to calculate the degree of labeling by reference to the relevant standard curve, and labeling values were used to determine regional labeling in each mouse.
Data processing. All calculations and graph preparation were performed using SigmaPlot for Windows, version 5.0 (Jandel Scientific, San Rafael, CA). Statistical analysis (one-way ANOVA) was performed using SPSS PCϩ (Jandel Scientific). Duncan's post hoc test was used to test for within-region differences. (Whiteaker et al., 2000b) , with the greatest amounts seen in optic tract-associated nuclei (superior colliculus, olivary pretectal nucleus, and the ventrolateral and dorsolateral geniculate nuclei) and the occulomotor nerve and more moderate expression throughout the dopaminergic tracts (substantia nigra, ventral tegmental region, striatum, nucleus accumbens, and olfactory tubercles) (Fig. 1,  fourth column) . Some developmental differences were evident, however: the amounts of [
RESULTS
Effect of
125 I]␣-CtxMII binding observed in the younger animals were generally higher than those seen in more mature animals (Whiteaker et al., 2000b (Figs. 1 and 3) . Indeed, the A85380-resistant binding sites in these regions were by far the most densely expressed nAChR population measured in the present study. Both of these findings are consistent with those reported for A85380-resistant binding in adult animals (Whiteaker et al., 2000a) , although the accessory olfactory bulbs of the younger animals used in this study were almost devoid of A85380-resistant [
125 I]epibatidine binding (2.3 Ϯ 0.4 and 1.0 Ϯ 0.2 fmol/mg protein in the glomerular and mitral layers, respectively), unlike those of adult animals (82 Ϯ 9 and 38 Ϯ 3 fmol/mg, respectively).
In contrast to [ 125 I]␣-CtxMII-binding nAChRs, the A85380-resistant nAChR population displayed notable sensitivity to the loss of ␣3 subunit expression, as illustrated in Figure 3 and detailed in Table 1 . As shown in Figure 3 ( first column) resistant binding in mutant animals was only 9.0 and 5.5% of that seen in wild-type mice in the fasciculus retroflexus and medial habenula, respectively. Outside the dorsal cortex of the inferior colliculus and the MH-IPN tract, only the medial vestibular and prepositus hypoglossal nuclei contained substantial amounts (Ͼ10 fmol/mg protein) of A85380-resistant [ 125 I]epibatidine binding (Fig. 3, fourth column) mice were seen, suggesting that loss of one copy of the ␣3 gene has very little effect on nAChR expression.
DISCUSSION
␣3 was the first mammalian neuronal nAChR subunit cloned (Boulter et al., 1986) and one of the first to be studied in an heterologous expression system (Boulter et al., 1987) . The immunochemical study by Flores et al. (1996) established the existence of ␣3␤4 nAChRs in the rat trigeminal ganglion, but functional (Zoli et al., 1998; Quick et al., 1999; Grady et al., 2001) , immunohistochemical (Yeh et al., 2001) , and binding (Whiteaker et al., 2000a) studies have provided only circumstantial evidence for central expression of ␣3* nAChRs. The findings of the present study provide the first direct evidence for ␣3* nAChR expression in the mammalian CNS. Expression of [ 125 I]␣-CtxMII-binding sites is independent of ␣3 nAChR subunit expression in 16 of the 18 regions in which these sites were identified (Fig. 2) . These data indicate that [
125 I]␣-CtxMII-binding nAChRs are largely not ␣3-dependent, despite being found in regions (the optic tract and its associated nuclei and dopaminergic terminal regions) in which ␣3 protein might be expected to be expressed, based on the detection of ␣3 mRNA (Wada et al., 1989; Whiteaker et al., 2000b) . This result was very surprising, because ␣-CtxMII was originally isolated by virtue of its selectivity for heterologously assembled ␣3␤2-subtype nAChRs (C artier et al., 1996) , and both ␣-C txM II and [
125 I]␣-C txM II display similar affinities at native [ 125 I]␣-C txM II-binding nAChRs and artificially expressed ␣3␤2-subtype nAChRs (Whiteaker et al., 2000b) . The lack of effect of ␣3 subunit deletion on [
125 I]␣-C txM II-binding nAChRs argues strongly against a role for the ␣3 nAChR subunit in this binding site.
Recently, it has been established that ␣6-containing nAChRs can bind ␣-CtxMII with high (nanomolar) affinity (Vailati et al., 1999; Kuryatov et al., 2000; Klink et al., 2001 ). In addition, the ␣6 nAChR subunit is widely coexpressed with ␣3 ( LeNovère et al., 1996) , and the two subunits exhibit considerable sequence homology (LeNovère and Changeux, 1995) . Together, these findings suggest that the majority of mouse brain [
125 I]␣-CtxMII-binding nAChRs may in fact be of an ␣6-containing rather than ␣3-containing subtype as originally suspected. A component of nAChR-stimulated striatal dopamine release is sensitive to inhibition by ␣-CtxMII (Kulak et al., 1997; Kaiser et al., 1998; Grady et al., 2001) , establishing that ␣-CtxMII-sensitive nAChRs are a functional mammalian neuronal nAChR subtype. In addition, striatal ␣-CtxMII-sensitive sites are dependent on ␤2 nAChR subunit expression (Grady et al., 2001) -IPN tract region) approached, but did not attain, significance (F (2,3) ϭ 4.89; p ϭ 0.11). The regression line (solid line) was fit to all regions that were not significantly different between genotypes; also shown are 95% confidence intervals (dotted lines). B, Withinregion differences were tested for in the habenulo-IPN tract using Duncan's post hoc test. Significant differences are denoted h (different from heterozygous null-mutant) or w (different from wild type). fr, Fasciculus retroflexus.
CtxMII-binding nAChRs are relatively rare. For instance, [
125 I]␣-CtxMII-binding sites are outnumbered by both cytisinesensitive and A85380-resistant [
125 I]epibatidine-binding sites in the terminal regions of the substantia nigra/ventral tegmental area dopaminergic projections. It is likely, however, that their concentration on dopaminergic termini strengthens their influence over this important pathway (Kulak et al., 1997; Kaiser et al., 1998; Grady et al., 2001; Quik et al., 2001 The agonist A85380 has been used to isolate the population of [
125 I]epibatidine-binding nAChRs with low affinity for both cytisine and ␣-CtxMII (Whiteaker et al., 2000a) . The distribution of A85380-resistant [
125 I]epibatidine-binding sites was very different from that of [
125 I]␣-CtxMII-binding nAChRs, demonstrating that two different populations of sites were being identified (Fig. 1) . In the regions containing the highest levels of A-85380-resistant binding (medial habenula-fasciculus retroflexus-IPN tract, dorsal cortex of the inferior colliculus, and medial vestibular and prepositus hypoglossal nucleus), binding was dramatically reduced in ␣3-null mutant animals. (Whiteaker et al., 2000a) . Second, the activation and binding pharmacology of receptors that persist in the habenulointerpeduncular tract of ␤2-null mutant mice also resemble that of ␣3␤4* nAChRs (Zoli et al., 1998; Grady et al., 2001 ). Third, central ␣3 subunit immunoreactivity is concentrated in habenulointerpeduncular tract nuclei (Yeh et al., 2001 ). Thus, the past and present findings strongly suggest that A85380-resistant epibatidine-binding sites correspond to a functional CNS ␣3␤4 nAChR subtype similar to that previously identified in the periphery (Flores et al., 1996) .
Widely distributed but low-density (Ͻ10 fmol/mg protein) A85380-resistant [ 125 I]epibatidine (100 pM) binding was observed (Figs. 1, 3 , Table 1 ). In particular, A85380-resistant sites were found in the optic tract and associated nuclei and in the cell body regions of the dopaminergic tract. However, these additional [
125 I]epibatidine-binding sites exhibited much lower ␣3 dependence than those in the more densely expressing regions. Given the generally lower affinity of A85380 at ␤4-versus ␤2-containing nAChR subtypes (Parker et al., 1998) , it is possible that these sites represent a combination of ␤4 with a non-␣3 subunit. Loss of ␣3 expression results in a syndrome with features suggestive of widespread autonomic dysfunction that is lethal within weeks of birth (Xu et al., 1999) . This dysfunction might theoretically induce global alterations in nAChR expression. However, the minor effects of ␣3-null mutation on [ 125 I]␣-CtxMII and total [
125 I]epibatidine-binding sites (Fig. 4 ) strongly argue against a generalized disruption of nAChR expression. In addition, the early demise of the ␣3 Ϫ/Ϫ mice necessitated the use of relatively young mice (8 d of age) in this study. It was anticipated that these mice might display major developmental differences in the distribution of nAChR subtypes compared with the more mature 60-to 90-d-old animals used in previous studies from our laboratory. In fact, each of the subtypes measured previously was found in the younger subjects used in this study. Regional distribution of the sites was qualitatively similar to that of adult mice, although some quantitative differences were seen.
In summary, this study has determined the ␣3 dependence of two previously identified nicotinic binding populations and has provided evidence for the possible existence of additional minor populations. Studies performed with transfected oocytes indicated that ␣3␤2 nAChRs have a high affinity for ␣-CtxMII. 
